Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy results of a randomized phase II clinical trial (NSCLC-TKD/IL-2) (Eudra-CT Number 2008-002130-30)
Multhoff G, Combs SE, Seier S, Stangl S, Sievert W, Shevtsov M, Blankenstein C, Hildebrandt M, Kokowski K, Hautmann M, Hautmann H, Roedel C, Fietkau R, Huber RM, Haller B, Ertl C, Devecka M, Offner R, Ahrens N (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: AMER ASSOC CANCER RESEARCH
City/Town: PHILADELPHIA
Conference Proceedings Title: CANCER RESEARCH
DOI: 10.1158/1538-7445.AM2020-LB-076
Authors with CRIS profile
Involved external institutions
Klinikum rechts der Isar
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
München Klinik Bogenhausen
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
München Klinik Bogenhausen
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
How to cite
APA:
Multhoff, G., Combs, S.E., Seier, S., Stangl, S., Sievert, W., Shevtsov, M.,... Ahrens, N. (2020). Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy results of a randomized phase II clinical trial (NSCLC-TKD/IL-2) (Eudra-CT Number 2008-002130-30). In CANCER RESEARCH. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
MLA:
Multhoff, Gabriele, et al. "Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy results of a randomized phase II clinical trial (NSCLC-TKD/IL-2) (Eudra-CT Number 2008-002130-30)." Proceedings of the AACR Annual Meeting PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2020.
BibTeX: Download